Table 4.
Ingenuity pathway analysis results
| Comparison group | Pathway | p-value | Z-score |
|---|---|---|---|
| All PDR vs. All CTL | Glycolysis I | 2.51E−08 | 3.32 |
| All PDR vs. All CTL | Gluconeogenesis I | 8.91E−07 | 3.16 |
| All PDR vs. All CTL | Protein kinase A signaling | 3.63E−02 | 2.98 |
| All PDR vs. All CTL | NRF2-mediated oxidative stress response | 1.05E−02 | 2.24 |
| All PDR vs. All CTL | SPINK1 pancreatic cancer pathway | 3.63E−04 | 2.12 |
| All PDR vs. All CTL | Semaphorin neuronal repulsive signaling pathway | 5.75E−03 | − 2.53 |
| All PDR vs. All CTL | IL-15 production | 9.12E−04 | − 2.71 |
| All PDR vs. All CTL | LXR/RXR activation | 1.58E−37 | − 2.95 |
| All PDR vs. All CTL | Synaptogenesis signaling pathway | 2.82E−08 | − 3.02 |
| PDR-L vs. CTL | Protein kinase A signaling | 3.63E−02 | 3.44 |
| PDR-L vs. CTL | Glycolysis I | 2.51E−08 | 3.32 |
| PDR-L vs. CTL | Gluconeogenesis I | 8.91E−07 | 3.16 |
| PDR-L vs. CTL | GP6 signaling pathway | 1.00E−10 | 2.40 |
| PDR-L vs. CTL | NRF2-mediated oxidative stress response | 1.05E−02 | 2.24 |
| PDR-L vs. CTL | Dendritic cell maturation | 1.15E−03 | 2.14 |
| PDR-L vs. CTL | BAG2 signaling pathway | 4.27E−02 | 2.00 |
| PDR-L vs. CTL | Extrinsic prothrombin activation pathway | 1.58E−11 | − 2.00 |
| PDR-L vs. CTL | Dermatan sulfate degradation (Metazoa) | 4.27E−03 | − 2.00 |
| PDR-L vs. CTL | IL-15 production | 9.12E−04 | − 2.11 |
| PDR-L vs. CTL | Chondroitin sulfate degradation (Metazoa) | 4.79E−04 | − 2.24 |
| PDR-L vs. CTL | Synaptogenesis signaling pathway | 2.82E−08 | − 2.65 |
| PDR-L vs. CTL | LXR/RXR activation | 1.58E−37 | − 3.24 |
| PDR-M vs. CTL | Glycolysis I | 1.51E−10 | 3.32 |
| PDR-M vs. CTL | Gluconeogenesis I | 3.24E−09 | 3.16 |
| PDR-M vs. CTL | SPINK1 pancreatic cancer pathway | 5.89E−04 | 2.83 |
| PDR-M vs. CTL | NRF2-mediated oxidative stress response | 1.78E−02 | 2.24 |
| PDR-M vs. CTL | LXR/RXR activation | 1.58E−37 | − 2.06 |
| PDR-M vs. CTL | Glioma invasiveness signaling | 3.02E−02 | − 2.45 |
| PDR-M vs. CTL | Synaptogenesis signaling pathway | 7.76E−08 | − 2.65 |
| PDR-M vs. CTL | IL-15 production | 1.62E−03 | − 2.71 |
| PDR-M vs. CTL | Semaphorin neuronal repulsive signaling pathway | 8.51E−03 | − 3.16 |
| PDR-H vs. CTL | Glycolysis I | 2.51E−08 | 3.32 |
| PDR-H vs. CTL | Gluconeogenesis I | 8.91E−07 | 3.16 |
| PDR-H vs. CTL | Protein kinase A signaling | 3.63E−02 | 2.98 |
| PDR-H vs. CTL | NRF2-mediated oxidative stress response | 1.05E−02 | 2.24 |
| PDR-H vs. CTL | SPINK1 pancreatic cancer pathway | 3.63E−04 | 2.12 |
| PDR-H vs. CTL | Leukocyte extravasation signaling | 3.89E−02 | 2.11 |
| PDR-H vs. CTL | Complement system | 2.00E−31 | 2.07 |
| PDR-H vs. CTL | IL-15 production | 9.12E−04 | − 2.11 |
| PDR-H vs. CTL | LXR/RXR activation | 1.58E−37 | − 2.36 |
| PDR-H vs. CTL | Semaphorin neuronal repulsive signaling pathway | 5.75E−03 | − 2.53 |
| PDR-H vs. CTL | Synaptogenesis signaling pathway | 2.82E−08 | − 2.65 |
Pathway analysis results obtained using Ingenuity Pathway Analysis (IPA; Qiagen). All individually treated PDR samples were compared to all individually treated experiment 2 control samples (All PDR v.s All CTL). PDR subphenotypes were also compared to all control samples
CTL control, DE differentially expressed